Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 20 studies | 44% ± 11% | |
lung | 16 studies | 31% ± 9% | |
brain | 11 studies | 31% ± 13% | |
intestine | 6 studies | 20% ± 4% | |
kidney | 5 studies | 33% ± 12% | |
eye | 4 studies | 34% ± 14% | |
lymph node | 4 studies | 28% ± 5% | |
breast | 4 studies | 20% ± 3% | |
liver | 4 studies | 40% ± 12% | |
adipose | 4 studies | 39% ± 8% | |
bone marrow | 3 studies | 33% ± 13% | |
heart | 3 studies | 22% ± 8% | |
uterus | 3 studies | 24% ± 6% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 11323.69 | 1445 / 1445 | 100% | 47.66 | 183 / 183 |
breast | 100% | 11726.91 | 459 / 459 | 99% | 44.34 | 1111 / 1118 |
stomach | 100% | 10127.46 | 359 / 359 | 99% | 38.68 | 283 / 286 |
lung | 100% | 21755.03 | 578 / 578 | 99% | 38.24 | 1142 / 1155 |
thymus | 100% | 18717.58 | 653 / 653 | 99% | 21.71 | 598 / 605 |
intestine | 100% | 13703.97 | 966 / 966 | 98% | 29.79 | 518 / 527 |
bladder | 100% | 11611.67 | 21 / 21 | 98% | 32.66 | 494 / 504 |
skin | 100% | 10771.92 | 1807 / 1809 | 98% | 28.27 | 462 / 472 |
uterus | 100% | 11798.91 | 170 / 170 | 97% | 30.02 | 447 / 459 |
kidney | 100% | 20380.11 | 89 / 89 | 97% | 37.18 | 870 / 901 |
ovary | 100% | 10221.17 | 180 / 180 | 95% | 28.14 | 409 / 430 |
liver | 100% | 6743.25 | 226 / 226 | 95% | 20.04 | 385 / 406 |
pancreas | 96% | 6529.25 | 315 / 328 | 97% | 25.46 | 173 / 178 |
prostate | 100% | 12826.30 | 245 / 245 | 93% | 17.00 | 468 / 502 |
brain | 87% | 4050.27 | 2306 / 2642 | 95% | 16.01 | 670 / 705 |
adrenal gland | 100% | 17571.22 | 258 / 258 | 75% | 9.40 | 173 / 230 |
adipose | 100% | 12199.52 | 1204 / 1204 | 0% | 0 | 0 / 0 |
spleen | 100% | 31259.46 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 31.56 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 12.18 | 1 / 1 |
blood vessel | 100% | 10223.28 | 1333 / 1335 | 0% | 0 | 0 / 0 |
peripheral blood | 99% | 21520.42 | 919 / 929 | 0% | 0 | 0 / 0 |
muscle | 98% | 5611.44 | 788 / 803 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 97% | 40.41 | 28 / 29 |
heart | 96% | 5168.40 | 824 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 95% | 17.30 | 76 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0120323 | Biological process | lipid ubiquitination |
GO_0002376 | Biological process | immune system process |
GO_0016567 | Biological process | protein ubiquitination |
GO_0001525 | Biological process | angiogenesis |
GO_0098792 | Biological process | xenophagy |
GO_0051865 | Biological process | protein autoubiquitination |
GO_0006511 | Biological process | ubiquitin-dependent protein catabolic process |
GO_0140042 | Biological process | lipid droplet formation |
GO_0019216 | Biological process | regulation of lipid metabolic process |
GO_2000051 | Biological process | negative regulation of non-canonical Wnt signaling pathway |
GO_0002040 | Biological process | sprouting angiogenesis |
GO_0070534 | Biological process | protein K63-linked ubiquitination |
GO_0042742 | Biological process | defense response to bacterium |
GO_0005730 | Cellular component | nucleolus |
GO_0005811 | Cellular component | lipid droplet |
GO_0016020 | Cellular component | membrane |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0061630 | Molecular function | ubiquitin protein ligase activity |
GO_0046872 | Molecular function | metal ion binding |
GO_0005524 | Molecular function | ATP binding |
GO_0004842 | Molecular function | ubiquitin-protein transferase activity |
GO_0016887 | Molecular function | ATP hydrolysis activity |
Gene name | RNF213 |
Protein name | Ring finger protein 213 E3 ubiquitin-protein ligase RNF213 (EC 2.3.2.27) (EC 3.6.4.-) (ALK lymphoma oligomerization partner on chromosome 17) (E3 ubiquitin-lipopolysaccharide ligase RNF213) (EC 2.3.2.-) (Mysterin) (RING finger protein 213) |
Synonyms | ALO17 KIAA1554 C17orf27 MYSTR KIAA1618 |
Description | FUNCTION: Atypical E3 ubiquitin ligase that can catalyze ubiquitination of both proteins and lipids, and which is involved in various processes, such as lipid metabolism, angiogenesis and cell-autonomous immunity . Acts as a key immune sensor by catalyzing ubiquitination of the lipid A moiety of bacterial lipopolysaccharide (LPS) via its RZ-type zinc-finger: restricts the proliferation of cytosolic bacteria, such as Salmonella, by generating the bacterial ubiquitin coat through the ubiquitination of LPS . Also acts indirectly by mediating the recruitment of the LUBAC complex, which conjugates linear polyubiquitin chains . Ubiquitination of LPS triggers cell-autonomous immunity, such as antibacterial autophagy, leading to degradation of the microbial invader . Involved in lipid metabolism by regulating fat storage and lipid droplet formation; act by inhibiting the lipolytic process . Also regulates lipotoxicity by inhibiting desaturation of fatty acids . Also acts as an E3 ubiquitin-protein ligase via its RING-type zinc finger: mediates 'Lys-63'-linked ubiquitination of target proteins . Involved in the non-canonical Wnt signaling pathway in vascular development: acts by mediating ubiquitination and degradation of FLNA and NFATC2 downstream of RSPO3, leading to inhibit the non-canonical Wnt signaling pathway and promoting vessel regression . Also has ATPase activity; ATPase activity is required for ubiquitination of LPS . . |
Accessions | ENST00000508628.6 A0A0A0MTR7 Q63HN8 ENST00000319921.4 [Q63HN8-5] ENST00000573038.1 ENST00000582970.6 A0A0A0MTC1 I3L3H9 |